Credits Available: 4.75 hours of AMA PRA Category 1 Credit™; ABIM MOC

Description: Despite significant advancements in treatment, multiple myeloma remains an incurable disease, and nearly all patients experience relapse, often requiring increasingly complex therapeutic strategies.

With the rapid expansion of treatment options, particularly novel targeted therapies such as GPRC5D-directed approaches, the landscape of relapsed/refractory multiple myeloma (RRMM) management is evolving at an unprecedented pace. While these agents offer deep and durable remissions, their integration into clinical practice presents challenges in sequencing, toxicity management, and multidisciplinary coordination.

This educational initiative is designed to empower clinicians with the latest insights on GPRC5D-targeted therapies, facilitate the exchange of real-world clinical experience, and provide actionable strategies for optimizing patient outcomes. Through interactive discussions and expert-led guidance, participants will gain practical knowledge to navigate the complexities of RRMM treatment while fostering collaborative networks to enhance long-term patient care.

Join us to stay at the forefront of innovation in multiple myeloma management and elevate your clinical practice.

CME/CE Accreditation Information

If you already have a Gather-ed account, please login

Email:
Password:

Register

Step 1 of 3

This program is intended for:
Target Professions: DO, MD, Nurse Practitioner, Nurse, Physician Associate/Assistant
Target Specialties: Hematology, Hematology/Oncology, Oncology

Samer Al Hadidi

University of Arkansas for Medical Sciences

Samer Al Hadidi, M.D., M.S.(CRDSA), FACP, is an associate professor of Medicine. He earned his medical degree from University of Jordan, and his M.S.(CRDSA) at the School of Public Health and Biostatistics at the University of Michigan-Ann Arbor. Dr. Al Hadidi trained in Internal Medicine in Hurley Medical Center/Michigan State University and Hematology & Oncology in Baylor College of Medicine.

Dr. Al Hadidi research interests include plasma cell dyscrasias including multiple myeloma with a focus on drug development, cellular therapy, immunotherapy, health equity and medical education.